Literature DB >> 26969461

A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome.

T Kume1, M Calan2, O Yilmaz3, G U Kocabas4, P Yesil5, M Temur3, M Bicer6, O G Calan1.   

Abstract

CONTEXT: Adropin is a peptide hormone implicated in the regulation of insulin sensitivity and energy homeostasis. Polycystic ovary syndrome (PCOS) is a metabolic and reproductive disease associated with insulin resistance. It has been demonstrated that various inflammatory markers increased in PCOS including TNF-α. TNF-α regulates the secretion of certain peptides which play a crucial role in glucose and lipid homeostasis. There is also some evidence of a link between TNF-α and adropin.
OBJECTIVE: To ascertain whether there is an association between circulating adropin levels and TNF-α in PCOS. PATIENTS AND
DESIGN: 152 women with PCOS and 152 age- and body mass index-matched controls without PCOS were recruited for this cross-sectional study. MAIN OUTCOME MEASURES: Adropin and TNF-α levels were measured using ELISA.
RESULTS: Adropin levels were lower in the PCOS group compared with the control group (7.43 ± 0.79 vs. 9.42 ± 0.76 ng/ml, P < 0.001), whereas TNF-α levels were higher (49.93 ± 3.39 vs. 35.83 ± 2.47 pg/ml, P < 0.001). A strongly negative correlation was found between circulating adropin levels and TNF-α levels in women with PCOS (r = -0.407, P < 0.001). Binary logistic regression analysis revealed that decreased adropin levels were significantly associated with high odds of having PCOS, although, after adjustment for TNF-α, this link vanished. Additionally, multiple linear regression analysis showed that HOMA-IR and TFN-α independently predicted adropin levels.
CONCLUSIONS: Serum adropin levels are significantly decreased in PCOS and are inversely associated with TNF-α. Further dissection of the nature of this association can open new therapeutic options for metabolic diseases.

Entities:  

Keywords:  Adropin; Cytokine; Insulin resistance; Polycystic ovary syndrome; Tumor necrosis factor-α

Mesh:

Substances:

Year:  2016        PMID: 26969461     DOI: 10.1007/s40618-016-0453-5

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  35 in total

1.  Adropin deficiency is associated with increased adiposity and insulin resistance.

Authors:  K Ganesh Kumar; Jingying Zhang; Su Gao; Jari Rossi; Owen P McGuinness; Heather H Halem; Michael D Culler; Randall L Mynatt; Andrew A Butler
Journal:  Obesity (Silver Spring)       Date:  2012-02-09       Impact factor: 5.002

2.  Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans.

Authors:  Andrew A Butler; Charmaine S Tam; Kimber L Stanhope; Bruce M Wolfe; Mohamed R Ali; Majella O'Keeffe; Marie-Pierre St-Onge; Eric Ravussin; Peter J Havel
Journal:  J Clin Endocrinol Metab       Date:  2012-08-07       Impact factor: 5.958

3.  Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus.

Authors:  Mustafa Topuz; Ahmet Celik; Tutku Aslantas; Ayse Kevser Demir; Suna Aydin; Suleyman Aydin
Journal:  J Investig Med       Date:  2013-12       Impact factor: 2.895

4.  Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation.

Authors:  Peter Plomgaard; Karim Bouzakri; Rikke Krogh-Madsen; Bettina Mittendorfer; Juleen R Zierath; Bente K Pedersen
Journal:  Diabetes       Date:  2005-10       Impact factor: 9.461

5.  Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea.

Authors:  Alexandros N Vgontzas; Georgia Trakada; Edward O Bixler; Hung-Mo Lin; Slobodanka Pejovic; Emmanuel Zoumakis; George P Chrousos; Richard S Legro
Journal:  Metabolism       Date:  2006-08       Impact factor: 8.694

6.  Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes.

Authors:  T G Kirchgessner; K T Uysal; S M Wiesbrock; M W Marino; G S Hotamisligil
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

7.  Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients.

Authors:  Lingzhen Wu; Jun Fang; Lianglong Chen; Ziwen Zhao; Yukun Luo; Chaogui Lin; Lin Fan
Journal:  Clin Chem Lab Med       Date:  2014-05       Impact factor: 3.694

8.  Adropin: a key component and potential gatekeeper of metabolic disturbances in policystic ovarian syndrome.

Authors:  B Yildirim; O Celik; S Aydin
Journal:  Clin Exp Obstet Gynecol       Date:  2014       Impact factor: 0.146

9.  Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism.

Authors:  K Ganesh Kumar; James L Trevaskis; Daniel D Lam; Gregory M Sutton; Robert A Koza; Vladimir N Chouljenko; Konstantin G Kousoulas; Pamela M Rogers; Robert A Kesterson; Marie Thearle; Anthony W Ferrante; Randall L Mynatt; Thomas P Burris; Jesse Z Dong; Heather A Halem; Michael D Culler; Lora K Heisler; Jacqueline M Stephens; Andrew A Butler
Journal:  Cell Metab       Date:  2008-12       Impact factor: 27.287

Review 10.  TNF-alpha, a potent lipid metabolism regulator.

Authors:  Xiuping Chen; Keli Xun; Lidian Chen; Yitao Wang
Journal:  Cell Biochem Funct       Date:  2009-10       Impact factor: 3.685

View more
  13 in total

1.  Fractalkine: an inflammatory chemokine elevated in subjects with polycystic ovary syndrome.

Authors:  İsmail Demi R; Aslı Guler; Pınar Alarslan; Ahmet Murat Isil; Ozge Ucman; Behnaz Aslanipour; Mehmet Calan
Journal:  Endocrine       Date:  2019-06-01       Impact factor: 3.633

2.  Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Orkide Kutlu; Özgür Altun; Okan Dikker; Şerife Aktaş; Neslihan Özsoy; Yücel Arman; Eylem Özgün Çil; Mustafa Özcan; Şengül Aydın Yoldemir; Murat Akarsu; İlkim Deniz Toprak; Kerem Kırna; Yasin Kutlu; Zeki Toprak; Hasan Eruzun; Tufan Tükek
Journal:  Med Princ Pract       Date:  2019-04-16       Impact factor: 1.927

Review 3.  Correlation Between Circulating Adropin Levels and Patients with PCOS: An Updated Systematic Review and Meta-analysis.

Authors:  Yani Ke; Jie Hu; Yuqing Zhu; Yaqin Wang; Shuaihang Chen; Shan Liu
Journal:  Reprod Sci       Date:  2022-01-11       Impact factor: 3.060

4.  Adropin and Inflammation Biomarker Levels in Male Patients With Obstructive Sleep Apnea: A Link With Glucose Metabolism and Sleep Parameters.

Authors:  Josko Bozic; Josip A Borovac; Tea Galic; Tina Ticinovic Kurir; Daniela Supe-Domic; Zoran Dogas
Journal:  J Clin Sleep Med       Date:  2018-07-15       Impact factor: 4.062

5.  UPLC/Q‑TOF‑MS based plasma metabolomics and clinical characteristics of polycystic ovarian syndrome.

Authors:  Xuemei Fan; Jianfa Jiang; Zhiqiang Huang; Jumei Gong; Yiming Wang; Wei Xue; Yan Deng; Yanfang Wang; Tingping Zheng; Aijun Sun; Guoan Luo
Journal:  Mol Med Rep       Date:  2018-11-12       Impact factor: 2.952

6.  Association of Serum Adropin Concentrations with Diabetic Nephropathy.

Authors:  Wenchao Hu; Li Chen
Journal:  Mediators Inflamm       Date:  2016-07-28       Impact factor: 4.711

7.  Serum adropin levels are reduced in patients with inflammatory bowel diseases.

Authors:  Darko Brnić; Dinko Martinovic; Piero Marin Zivkovic; Daria Tokic; Ivana Tadin Hadjina; Doris Rusic; Marino Vilovic; Daniela Supe-Domic; Ante Tonkic; Josko Bozic
Journal:  Sci Rep       Date:  2020-06-09       Impact factor: 4.379

8.  Plasma Adropin as a Potential Marker Predicting Obesity and Obesity-associated Cancer in Korean Patients With Type 2 Diabetes Mellitus.

Authors:  Ha-Neul Choi; Jung-Eun Yim
Journal:  J Cancer Prev       Date:  2018-12-30

9.  Assessment of Serum Concentrations of Adropin, Afamin, and Neudesin in Children with Type 1 Diabetes.

Authors:  Agnieszka Polkowska; Izabela Elżbieta Pasierowska; Marta Pasławska; Elżbieta Pawluczuk; Artur Bossowski
Journal:  Biomed Res Int       Date:  2019-10-24       Impact factor: 3.411

Review 10.  A Review of Adropin as the Medium of Dialogue between Energy Regulation and Immune Regulation.

Authors:  Shuyu Zhang; Qingquan Chen; Xuchen Lin; Min Chen; Qicai Liu
Journal:  Oxid Med Cell Longev       Date:  2020-03-04       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.